title: Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors.
abstract: OBJECTIVES: Drugs used for the treatment of rheumatoid arthritis (RA) have the potential to affect cardiovascular risk factors. There is concern that corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors could affect cardiovascular risk adversely, while drugs such as the antimalarial, hydroxychloroquine, may have beneficial effects. However, there is limited information about cardiovascular risk factors in patients with RA receiving different drugs. METHODS: We measured cardiovascular risk factors including systolic and diastolic blood pressure, serum HDL and LDL cholesterol, glucose and homocysteine concentrations and urinary F(2)-isoprostane excretion in 169 patients with RA. Risk factors were compared according to current use of corticosteroids, methotrexate, antimalarials, NSAIDs, COX-2 inhibitors, leflunomide and TNF-alpha blockers. Comparisons were adjusted for age, sex, race, disease activity (DAS28 score), current hypertension, diabetes, smoking status and statin use. RESULTS: No cardiovascular risk factor differed significantly among current users and non-users of NSAIDs, COX-2 inhibitors, methotrexate and TNF-alpha blockers. Serum HDL cholesterol concentrations were significantly higher in patients currently receiving corticosteroids (42.2 +/- 10.5 vs. 50.2 +/- 15.3 mg/dL, adjusted P < 0.001). Diastolic blood pressure (75.9 +/- 11.2 vs. 72.0 +/- 9.1 mm Hg, adjusted P = 0.02), serum LDL cholesterol (115.6 +/- 34.7 vs. 103.7 +/- 27.8 mg/dL, adjusted P = 0.03) and triglyceride concentrations (157.7 +/- 202.6 vs. 105.5 +/- 50.5 mg/dL, adjusted P = 0.03) were significantly lower in patients taking antimalarial drugs. Plasma glucose was significantly lower in current lefunomide users (93.0 +/- 19.2 vs. 83.6 +/- 13.4 mg/dL, adjusted P = 0.006). CONCLUSIONS: In a cross-sectional setting drugs used to treat RA did not have major adverse effects on cardiovascular risk factors and use of antimalarials was associated with beneficial lipid profiles.
authors.affiliation: Divisions of Clinical Pharmacology and Rheumatology, Vanderbilt University School of Medicine Nashville, TN, USA.
authors.forename: Young Hee
authors.initials: YH
authors.lastname: Rho
authors.forename: Annette
authors.initials: A
authors.lastname: Oeser
authors.forename: Cecilia P
authors.initials: CP
authors.lastname: Chung
authors.forename: Ginger L
authors.initials: GL
authors.lastname: Milne
authors.forename: C Michael
authors.initials: CM
authors.lastname: Stein
references.citation: Ren Fail. 1999 Mar;21(2):189-97
references.pmid: 10088179
references.citation: Arthritis Res Ther. 2006;8(6):R186
references.pmid: 17169159
references.citation: Am J Med. 1994 Mar;96(3):254-9
references.pmid: 8154514
references.citation: Arthritis Rheum. 2008 Sep;58(9):2662-9
references.pmid: 18759301
references.citation: J Rheumatol. 1986 Oct;13(5):841-5
references.pmid: 3820193
references.citation: Ann Rheum Dis. 2007 Nov;66(11):1503-7
references.pmid: 17472994
references.citation: Clin Physiol. 1993 Mar;13(2):209-16
references.pmid: 8453873
references.citation: J Clin Gastroenterol. 2001 Oct;33(4):289-94
references.pmid: 11588541
references.citation: Ann Rheum Dis. 2002 Jun;61(6):567-9
references.pmid: 12006342
references.citation: Arch Drug Inf. 2008 Jul;1(1):23-28
references.pmid: 20157365
references.citation: Nat Protoc. 2007;2(1):221-6
references.pmid: 17401357
references.citation: Rheumatology (Oxford). 2004 Mar;43(3):267-71
references.pmid: 14963199
references.citation: Drugs. 2002;62(4):605-16
references.pmid: 11893229
references.citation: N Engl J Med. 2007 Nov 22;357(21):2109-22
references.pmid: 17984165
references.citation: Can J Cardiol. 2000 Apr;16(4):505-11
references.pmid: 10787466
references.citation: Nature. 2006 Dec 14;444(7121):794-5
references.pmid: 17167436
references.citation: Curr Med Chem. 2007;14(6):703-17
references.pmid: 17346157
references.citation: N Engl J Med. 2006 Aug 31;355(9):873-84
references.pmid: 16943400
references.citation: Arthritis Res Ther. 2008;10(2):R30
references.pmid: 18325087
references.citation: Atherosclerosis. 2008 Feb;196(2):756-63
references.pmid: 17266963
references.citation: Ann Rheum Dis. 2007 Apr;66(4):558-9
references.pmid: 17360784
references.citation: Arthritis Rheum. 2005 Oct;52(10):3045-53
references.pmid: 16200609
references.citation: Arthritis Rheum. 1995 Jan;38(1):44-8
references.pmid: 7818570
references.citation: Arthritis Rheum. 2008 Jul;58(7):2105-12
references.pmid: 18576352
references.citation: Arthritis Rheum. 2001 May;44(5):1048-51
references.pmid: 11352235
references.citation: Lupus. 1996 Jun;5 Suppl 1:S16-22
references.pmid: 8803905
references.citation: N Engl J Med. 2005 Mar 17;352(11):1092-102
references.pmid: 15713943
references.citation: Lancet. 2002 Apr 6;359(9313):1173-7
references.pmid: 11955534